Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 883 |
| PDBID: | 4PGJ |
| Chains: | A_B |
| Organism: | Homo sapiens, Gallus gallus |
| Method: | XRD |
| Resolution (Å): | 2.60 |
| Reference: | 10.1074/jbc.M114.614842 |
| Antibody | |
| Antibody: | Human VHH |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | Lysozyme C |
| Antigen mutation: | No |
| Durg Target: | |
Sequence information
Antibody
Chain: A
Mutation: NULL
| >4PGJ_A|Chain A, C|Human heavy chain domain antibody|Homo sapiens (9606) EVQLLESGGGLVQPGGSLRLSCAASGFRFDAEDMGWVRQAPGKGLEWVSSIYGPSGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKYTSPPQNHGFDYWGQGTLVTVSS |
Antigen
Chain: B
Mutation: NULL
| >4PGJ_B|Chain B, D|Lysozyme C|Gallus gallus (9031) KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPCSALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| A: ASP33 VAL37 LEU45 TRP47 SER50 TYR52 TYR59 TYR99 THR100 SER101 PRO102 PRO103 GLN104 ASN105 HIS106 GLY107 PHE108 ASP109 TRP111 B: GLU35 ARG45 ASN46 THR47 ASP48 GLY49 ASP52 GLN57 ASN59 ARG61 TRP62 TRP63 PRO70 GLY71 ASP101 ASN103 ASN106 ALA107 TRP108 VAL109 ALA110 ARG112 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
